Asian Oncol Nurs.  2014 Mar;14(1):1-6. 10.5388/aon.2014.14.1.1.

Differential Diagnosis between Hand-foot Syndrome and Gout in Colorectal Cancer with Capecitabine: A Case Study and Review of the Literature

• Park JY

• KMID: 2269468
• DOI: http://doi.org/10.5388/aon.2014.14.1.1

Abstract

PURPOSE
This study is to present a case of a patient experiencing foot pain after being prescribed capecitabine and to review the differential diagnosis between hand-foot syndrome and gout.
METHODS
This case is an 89-year-old patient endorsed to an emergency department with a 2-day history of foot swelling and pain.
RESULTS
The old patient was treated with capecitabine which was orally administered twice daily for 2 weeks, followed by 1 week of rest. He experienced severe pain in his foot area during the 3rd chemotherapy cycle. Side effects must be assessed to keep treatment on course.
CONCLUSION
Clinical specialists should be knowledgeable of differential diagnosis.

Keyword

Colorectal Cancer; Elderly; Hand-Foot Syndrome; Gout; Capecitabine

MeSH Terms

Aged
Aged, 80 and over
Colorectal Neoplasms*
Diagnosis, Differential*
Drug Therapy
Emergency Service, Hospital
Foot
Gout*
Hand-Foot Syndrome*
Humans
Specialization
Capecitabine

Figure

• 

  Fig. 1 Patient-reported symptom. Erythema, Pain, and Edema of the Foot.

Reference

1. Hong YS, Kim TW. Chemotherapy for colorectal cancer. J Korean Med Assoc. 2010; 53(7):582–591.

2. Jung JM, Jung SA, Kim SE, Kang MJ, Shim KN, Kim KH, et al. Factors favoring survival in elderly patients with colorectal cancer. Korean J Med. 2009; 76(6):701–712.

3. Neuman HB, O'Connor ES, Weiss J, LoConte NK, Greenblatt DY, Greenberg CC, et al. Surgical treatment of colon cancer in patients aged 80 years and older. Cancer. 2013; 119(3):639–647.

4. Yarbro CH, Wujcik D, Gobel BH. Cancer symptom management. MA: Jones & Bartlett Learning;2014.

5. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest. 2002; 20(1):3–10.

6. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. National Cancer Institute No. 09-5410. 2009.

7. Song SJ. Clinical Manifestations and Diagnosis of Gout. J Korean Med Assoc. 2010; 53(8):695–704.

8. Seo YI, Son KM, Jung YO, Kim IJ, Kim KL, Bae YD, et al. Survey of current trends for diagnosis and treatment in Korean gout patients. J Rheum Dis. 2011; 18(3):187–192.